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Abstract
Shotgun proteomic data are affected by a variety of known and unknown systematic biases as well as high
proportions of missing values. Typically, normalization is performed in an attempt to remove systematic biases
from the data before statistical inference, sometimes followed by missing value imputation to obtain a complete
matrix of intensities. Here we discuss several approaches to normalization and dealing with missing values, some
initially developed for microarray data and some developed specifically for mass spectrometry-based data.
Background
High-throughput mass spectrometry (MS) has become an
important technology for protein identification and quan-
titation due to its ability to rapidly provide identification
and quantitation of thousands of peptides [1]. In this
manuscript we focus on the studies where proteins are
first digested into constitutive peptides by means of che-
mical or enzymatic digestion. Mixtures of peptides from
complex biological samples are generally subjected to
liquid chromatography (LC) to separate the peptides in
time such that the mass spectrometer is provided with
only a small portion of all peptides in a sample (based on
some physiochemical properties) at a given time. Separa-
tion allows for more peptides to be detected by the mass
spectrometer. The liquid coming from the LC separation
column is generally electrosprayed to form molecular ions
that are then subjected to MS or MS/MS analysis. The
resulting mass spectra are compared to the theoretical or
previously observed peptides to produce peptide identifi-
cations and subsequently quantitation of those peptides
(and often the parent proteins) [2-5].
Systematic bias is inherent in MS-based data due to
complex biological, experimental and technical processing.
Bias, which may be loosely defined as any non-biological
signal, may occur due to many factors, including variations
in sample processing conditions, instrument calibrations,
LC columns, changes in temperature over the course of an
experiment, etc. One may observe systematic biases in
mass measurement accuracy, LC retention times, and/or
peak intensities. In an effort to better enable comparisons
between samples, it is desirable to remove any excess tech-
nical variability by utilizing various normalization techni-
ques. For example, LC-MS samples may be aligned in
terms of their LC retention time and mass profiles, or
nonlinear modeling may be employed to capture systema-
tic errors in mass measurements [6] or peak intensities
[7-9]. Several normalization methods have been imported
from microarray studies such as central tendency, lowess
regression and quantile normalization [10,11]. Other
normalization methods were developed specifically for
MS-based proteomic data [8,9].
Another challenge in quantitative proteomics is wide-
spread missing data (i.e. missing identifications or abun-
dance values). A peptide intensity value may be missing
due to several mechanisms, including: (i) the peptide truly
is present at an abundance the instrument should be able
to detect, but is not detected or is incorrectly identified,
(ii) the peptide truly is present but at an abundance below
the instrument’s detection limits, and (iii) the peptide is
not present. Different methods for dealing with missing
values should be used depending on the mechanism that
gave rise to a missing value. In case (i), using observed
values to impute missing values or simply ignoring a few
missing values is appropriate. However in cases (ii) and
(iii), when a peptide abundance is below our ability to
detect it, simple imputations based on observed values are
not appropriate [12]. Such values are said to be censored;
ignoring or imputing censored values based on the
observed data will overestimate peptide abundances and
lead to biased results.
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Analysis of MS data almost always involves dealing
with both bias and missing values. Deciding which nor-
malization to use and when can be challenging. For
example, one needs to make a decision on whether to
impute the missing values first and normalize next, or
the other way around. All work is generally performed on
the logarithm (log) scale of the abundances/intensities.
This simplifies statistics that follow, as log abundances
are often approximately normally distributed. Logarithm
base two is preferred for the ease of fold change interpre-
tation but any logarithmic transformation will produce
approximately Normally distributed intensities. Here we
use terms abundance and intensity interchangeably.
Methods
Normalization
In the context of -Omics applications, bias can generally
be defined as non-biological signal; that is, systematic fea-
tures of the data that are entirely attributable to experi-
mental or technical aspects. There are many sources of
bias in LC-MS data, all of which have the potential to
affect the measured peptide/protein expression levels
(e.g., non-optimal ionization efficiencies in complex sam-
ples, differences in LC columns, differences in sample
preparation and data acquisition between technicians).
The term normalization refers to the process of removing
such biases. There are many different approaches, but we
focus our discussion on those that are most widely used
or have properties that work especially well for proteomic
data.
A global adjustment is often used to force the distribu-
tion of the log intensity values to center around a constant
such as mean, median or some fixed value for each sample
[7]. Here an assumption is made that most peptide abun-
dances do not change, so the distribution of intensities
across different samples should be similar. A constant may
also be based on a subset of peptides coming from known
conserved house-keeping proteins [13]. Global adjustment
can correct for differences in the amounts of material
loaded for each sample, but cannot capture more complex
(e.g., non-linear and intensity-dependent) biases.
Robust scatter plot smoothing or lowess regression is
another widely-used normalization technique adapted
from the microarray setting [7,11]. Scatterplot smoothing
techniques work with so-called MA plots (“minus vs.
average” for comparing the intensities of two samples).
These techniques were developed in the context of two-
color gene expression microarray studies, where two
fluorescent dyes are used on each array. While there is a
natural (internal) reference in two-color microarrays, in
proteomic studies a reference sample must be selected
against which all the other samples will be normalized.
Selection of such reference sample is usually arbitrary.
Lowess performs local linear fits dependent on the user-
defined fraction of points to be used for smoothing at
each point. The fraction value is mostly arbitrary and
suboptimal value may reduce the efficiency of the nor-
malization and result in poorly normalized data. Empiri-
cally selected value of 0.4 has been used in several studies
[7,10]. Berger et al. proposed an optimization-based pro-
cedure for estimating the fraction value [14]. Scatterplot-
smoothing techniques are able to capture non-linear
intensity-dependent biases and are therefore more flex-
ible than global adjustments.
ANOVA and regression models can effectively esti-
mate and remove systematic biases when sources of bias
are known exactly [15]. Consider an LC-MS experiment
in which protein- and peptide-level identifications are
obtained for samples from two or treatment groups,
with the samples run in two or more batches. A sensible
model would be:
yijkbl = Proti + Pepij + Treatik + Batchib + εijkbl (1)
Where yijkbl is the log-transformed peak abundance for
protein i, peptide j, comparison group k and batch b;
Proti is the overall mean intensity for protein i; Pepij is
the offset for peptide j from ith protein mean; Treatik and
Batchib are mean differences between treatment groups
and batches, respectively; and the ε term represents ran-
dom error. For a given protein, the peptide effects are
constrained to sum to zero; that is,j Pepij = 0. Similarly,
for a given protein, the treatment effects are constrained
to sum to zero; k Treatik = 0 and so do batch effect,
b Batchib = 0. The εijkbl term represents random error,
and follows the Normal distribution with mean zero and
variance σ 2ij assuming a separate error variance for each
peptide but a common variance for each treatment group
and batch in the same peptide. The model above can esti-
mate and eliminate bias attributable to batch effect, and
other terms can be added to the model to estimate other
known sources of variation. In the above model batch
effect would capture any variation due to samples pro-
cessed in one group or close proximity in time. An alter-
native model for abundance would replace our peptide
fixed effects with random effect, resulting in a mixed
effects model [16]. In cases when technical replicates are
obtained subject random effects also can be introduced.
The qualitative difference between the fixed and mixed
effects models would be minimal. However, it will not
generally be possible to identify all of the relevant sources
of bias to sufficiently model biases with ANOVA.
Furthermore, biases due to batch effects, say, are likely to
be more complex than simple constant shifts, like those
specified in model (1). More realistically, biases would be
modeled via flexible nonlinear functions, but this compli-
cates the analysis [17]; see Supervised Normalization of
Microarrays (SNM) for a slick solution in the microarray
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setting [18]. Finally, the use of peptide-specific models for
preprocessing may overfit the data and invalidate down-
stream statistical inference [19].
EigenMS, an adaptation of surrogate variable analysis
for microarrays [17], was developed specifically for MS
data [8]. EigenMS uses singular value decomposition
(SVD) on model residuals to identify trends attributable
to bias. This allows for bias of arbitrary complexity to be
captured as ‘eigenpeptides’ and subsequently removed.
This means that the researchers do not need to know
sources of bias to be able to remove them. EigenMS has
several beneficial features for proteomics data normaliza-
tion. First, it is applicable to data with widespread miss-
ing values, as is common in MS-based proteomics.
Second, the EigenMS algorithm is well-suited for inclu-
sion in an existing proteomics analysis pipeline, as it does
not require any special downstream steps or housekeep-
ing. Automated selection of the number of significant
bias eigentrends simplifies the normalization process,
which can be applied to identified peptide abundances or
abundances of unidentified features.
When doing differential expression analysis it is advised
to check the distribution of the p-values as a diagnostic
plot. Figure 3 (left panel) shows the distribution of p-values
under the null hypothesis, i.e. no differential expression.
As expected the p-values are approximately uniformly dis-
tributed on the [0 1] interval [20,21]. Figure 3 (right panel)
shows skewed distribution of p-values which may indicate
overfitting and/or confounding.
Missing values
Missing values are common in MS data and are a key chal-
lenge in quantitative proteomics. Missing values arise
when, for example, a peptide is identified in some samples
but not in others; for the samples in which the peptide was
not identified, abundances are not assigned or are assigned
NA (not a number). A peptide may be missing because it
is not present in the sample, it may be present but at a
concentration below instrument detection limit, or may be
present and not identified correctly or detected due to
some unknown effect. Generally one cannot easily distin-
guish why peptide abundance is missing. What we do with
the missing values, on the other hand, should ideally rely
on the mechanism that caused the values to be missing.
For example, we can usually separate missing values into
two categories: missing completely at random (MCAR)
and abundance-dependent missing values. MCAR values
occur due to some “glitches” in the instrumentation, such
as poor ionization, other peptides competing for charge,
etc. This means that the fact that a peptide was unobserved
in a sample has nothing to do with its abundance or the
abundances of other peptides. Such peptide measurements
can be described as missing in an “abundance-indepen-
dent” manner. Random missingness is expected to affect a
relatively small proportion of the peptides [22]. Meanwhile,
“abundance-dependent” missingness in MS data boils
down to censoring. In this case, a peptide abundance falls
below the instrument detection limit or a peptide is simply
not present. Knowing that a peptide is censored gives us
partial information about the peptide intensity, in that we
know it must be less than the detection limit of the instru-
ment. This is an example of left-censoring. Right-censoring
would occur if the detector were to get saturated with sig-
nal and fail to record abundances above a certain thresh-
old. Right-censoring is less-commonly observed in current
MS-based proteomics.
Values missing completely at random (MCAR) can be
imputed by simple methods, although some methods
are better than others [12]. For example, imputing
MCAR values with row means or lowest observed value
is computationally very fast and easy to implement, but
imputing multiple values with the same value will
underestimate the true biological variation as the num-
ber of imputed values increases. On the other hand,
given a reasonable number of observations for a peptide,
MCAR values can be imputed from an empirical prob-
ability distribution. For instance, log-transformed inten-
sities across samples are approximately Normally
distributed, making it possible to impute MCAR mea-
surements from the Normal distribution with mean and
variance estimated from the observed data. The values
imputed in such a way will vary and thus variance
underestimation will not be as large an issue. Missing
values from different disease groups may need to be
imputed from distinct distributions, as means of those
disease groups may be different. Imputation of MCAR
and effects of the imputation method on subsequent
inference has been heavily studied in microarray data
and most methods used in proteomics are inherited
from microarray analysis [23].
Censored data present a more complicated problem,
as observed values are not a good basis for imputation.
In this scenario, censored values are said to be informa-
tive, in that the fact that a peptide was not observed
tells us that its abundance was simply below our ability
to detect it. The observed values for a peptide are not
representative of the unobserved values, and analyzing
only the observed values or performing imputation
based on their average, or even random values generated
from an estimated probability distribution as described
above, will result in upward-biased estimates and down-
ward-biased standard errors.
Figure 1 shows peptide intensities for two treatment
groups with (A) no missing values, (B) MCAR missing
values, (C) censored missing values, and (D) censored
missing values imputed as a minimum observed value.
Blue lines represent the true group mean and black
dashed lines represent the mean estimated with missing
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or imputed values. Importantly, it is hard to tell in prac-
tice whether a missing observation is censored or
MCAR; a proper probability model can help [22,24].
Figure 2 shows actual coverage proportions for nominal
95% confidence intervals of protein-level differences,
based on 100 simulations of 200 proteins with varying
numbers of peptides. Percent missing values was varied
from 0% to 40% with 5% missing MCAR values in all
but the 0% missing dataset. Whereas we expect 95% of
all 95% confidence intervals to contain their true para-
meter value, actual coverage decreases sharply as the
number of censored values increases.
In prior work, we proposed a statistical framework for
protein quantitation and inference in the presence of
values missing completely at random as well as censored
[22]. Our model for protein-level abundance is similar to
that in Equation 1:
yijkl = Proti + Pepij + Treatik + εijkl (2)
A maximum likelihood model is employed that
expresses protein-level abundances in terms of peptide-
level abundances and accounts for the two types or miss-
ingness. Statistical inference proceeds by numerically opti-
mizing the maximum likelihood model to obtain p-values
for differential protein expression. It is also possible to use
rough parameter estimates to perform model-based filter-
ing and imputation without the use of numerical optimiza-
tion to obtain imputed values for future inference. Note
that model (2) represents one approach for ‘rolling up’
peptide-level information to the protein level. In general,
peptide-to-protein rollup is a complex exercise, and others
have taken a variety of approaches [25,26].
In the automated filtering routine, information content
from maximum likelihood theory guides the selection and
Figure 1 Examples of missing data. Intensities for a peptide with two treatment groups with (A) no missing values, (B) MCAR missing values,
(C) censored missing values, and (D) censored missing values imputed as a minimum observed value.
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exclusion of peptides and proteins. Model (2) is con-
structed under the assumption that primary interest is in
protein-level group differences; this would make the
Treatik the parameters of interest. For any protein and a
set of peptides within that protein, the Fischer information
matrix is estimated and information content is quantified
for the protein-level group difference parameters by taking
the scaled determinant of the corresponding matrix block.
Proteins are filtered if no collection of peptides produces
an identifiable model, with non-zero information matrix
Figure 2 Percent coverage for nominal 95% confidence intervals of protein-level differences.
Figure 3 Histograms of the null p-values for normalized (left) and raw (right) peptide abundances.
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determinant. A greedy search algorithm is then used to
select a subset of peptides for each remaining protein that
produce an optimal information content. The remaining
peptides are filtered out. Further, an imputation routine
generates values for missing observations from a normal
distribution. The values are generated from a left hand tail
of the distribution (below a censoring cutoff) if an observa-
tion is determined to be censored and from the complete
normal distribution if it is determined to be MCAR. A
single imputation is carried out and p-values are adjusted
to minimize the effect of possible overfitting. P-value
adjustment relies on the assumption that null p-values are
uniformly distributed and thus the histogram of p-values
should look flat with a spike at the small p-values; these
are differentially expressed proteins. A deviation from
such a picture may be indicative of overfitting (in the non-
normalized p-value histogram, it may indicate bias).
Adjustment is performed to assure that null p-values are
approximately uniformly distributed. Since in biological
samples it is not known which proteins are differentially
expressed and which ones are not, only the right tail of the
p-value distribution is considered as true null p-values in
the adjustment. The algorithm is implemented in the Dan-
teR statistical software toolbox available at: http://omics.
pnl.gov/software/ and from the author’s website.
Luo et al. 2009 proposed a Bayesian approach to deal-
ing with censored (they call them non-randomly missing)
observations in iTRAQ (isobaric Tags for Relative and
Absolute Quantitation) data. The authors use logistic
regression to determine if a peptide is censored or
MCAR. This is based on the assumption that there is a
negative correlation between probability of missing value
and peptide abundance and an approximate linear rela-
tionship between the missing peptide probability and the
observed intensity at the logit scale. Logistic regression is
a nice fit for a problem where a distinction needs to be
made between only two classes, here they are censored
and MCAR values. Although the authors apply their
model to labeled data, it can also be applied to unlabeled
MS data. The authors perform inference while taking
into account censored missing values but no model for
actual imputation of missing values is proposed. In this
sense, using the proposed approach is similar to using
the maximum likelihood model (Karpievitch et al. 2009b)
to obtain the p-values for differential expression; we can
get the p-values but not the p-values for imputed data.
No implementation has been made available to the public
as described in the manuscript.
The choice of thresholds to use when identifying pep-
tides is related to the problem of missing values, although
the specific nature of this relationship is not known.
Lowering the amount of evidence required for identifying
peptides (lowering the threshold) will result in more pep-
tides and peak intensities but will not necessarily result
in a decrease in the number of missing values. In fact, it
might be expected that lower identification thresholds
will lead to a greater number of missing values, since a
greater proportion of the additional peptides are liable to
be false identifications. Having said that, a careful exami-
nation of these issues would make for interesting future
work.
Missing values may also occur due to the limited
depth of coverage of the instruments. In MS/MS identi-
fication, generally only a small portion of the most
abundant peptides at a given time (MS1) are selected for
further fragmentation and identification in the MS2
phase. Thus, if a peptide is of lower abundance in one
treatment group vs. the other it may not be identified if
there are enough more-abundant peptides in the same
MS scan. This issue can be addressed by selecting speci-
fic masses for further fragmentation instead of the top
most abundant peptides.
Impact of complex preprocessing on downstream
statistical inference
Normalization and missing value imputation generally
occur as preprocessing steps followed by statistical infer-
ence to answer questions of primary scientific interest.
However, all data processing, including both preproces-
sing and downstream inference, “uses up” some of the
information in the data to fit and employ statistical or
mathematical models. Ideally, a single statistical model
would be used to simultaneously carry out preproces-
sing and inference [18]. We might represent this model
as such:
Data = Technical Signal + Biological Signal + Random Error (3)
where Technical Signal represents any systematic
biases as well as missing-data patterns, and Biological
Signal represents systematic biological differences
between comparison groups of interest.
The most natural approach to data analysis based on
the above model would be to fit it in a single step. This
would correspond to carrying out preprocessing and
inference simultaneously. In practice, the typical analysis
pipeline, composed of preprocessing steps followed by
downstream inference, is analogous to first fitting the
model:
Data = Technical Signal + Random Error (4)
then carrying out inference on the basis of the model:
Residuals = Biological Signal + Random Error (5)
where Residuals are the processed (normalized) data.
The problem with this approach is that the variability
introduced into the pipeline from the first step is not
communicated to the second step. In other words, any
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degrees of freedom that are used up in the preproces-
sing model are not discounted when using the second
model for inference. This can lead to an “overfitting” of
the data, whereby resulting statistical inferences are not
directly interpretable [27].
As mentioned above, to minimize the issues of overfit-
ting, inference and normalization can be carried out
simultaneously [18,21]. If that is not possible, in cases
when normalized data needs to be passed over to investi-
gators, additional variables can be provided that should
be used in further analysis together with the normalized
data [17]. Such variables can be stored and plugged-in as
covariates in the significance-testing model, for example,
added to the regression model matrix. Carry-over vari-
able are not always feasible and there is no guarantee
that the collaborators will actually use them in the future
significance analysis. To avoid the requirement for carry-
over variables, methods that adjust for possible overfit-
ting should be applied to the normalized data [8]. This
approach adds random variability to the model residuals
to effectively remove the appropriate number of degrees
of freedom. This allows for post-normalization signifi-
cance analysis with no special steps required; that is, no
additional covariates need to be added to the inference
model, and no adjustment to the null sampling distribu-
tion of test statistics are required.
Combining normalization and missing value imputation
At this point we have shown that systematic bias and
missing observations are prevalent in MS-based data. The
fact that many normalization routines require a ‘complete’
matrix with no missing values, raises a question: should
the imputation be done first followed by normalization?
That seems like a reasonable solution at first. For example,
one can impute missing values using one of the methods
described above to produce a complete matrix, and then
use one of the normalization routines to remove bias. At
this time one should wonder if the imputation was to be
repeated would the values be different and would that
affect normalization? The answer is generally, yes, imputed
values will be different every time because they are drawn
at random from an appropriate distribution. Thus,
imputed values, especially if there is a high proportion of
those, can potentially obscure the bias trends and prevent
normalization routines from effectively removing it. More-
over, it does not make sense to impute missing values
based on biased observations.
We show the impact that normalization and imputa-
tion and the order of those procedures may have on the
processed data and significance analysis by using simu-
lated data. Simulated data were created with 10 samples
in each of two treatment groups (20 samples total). The
size and structure of the simulated data were selected to
mimic those in a real dataset composed of human sub-
jects. Specifically, 1400 proteins were simulated with
varying numbers of peptides per protein and 13% of
missing values. Proportion MCAR values was simulated
to be 5% and 8% censored values. Simulated data were
generated from model (6), which is an adaptation of
model (1) that (through the Sampim terms) allows for
sample-specific variation in the peptide abundances,
such as might be induced by differences in the loading
amounts from sample to sample:
yijkl = Proti + Pepij + Treatik + Sampim + εijkl (6)
The index m is for sample, and the remaining model
terms are as in model (1). We perform (i) imputation fol-
lowed by normalization and (ii) normalization followed
by imputation. We use normalization and imputation
methods described in Karpievitch et al. 2009a and 2009b,
but any other appropriate methods will have similar
effects. Figure 4 shows the eigentrends in raw (top left),
residual (top right), imputed (bottom left), imputed and
normalized (normalized and imputed) data; the top three
trends are shown for each subplot. Eigentrends are trends
identified in the data by using SVD, and they capture
major variations in the data. In the differential expression
(DE) studies one would ideally like to see a step function
Figure 4 Top three eigentrends identified in raw (left), imputed (middle); and normalized after imputation data (right). X-axis is the
sample index, y-axis are values in eigentrends.
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for each group, reflecting mean differences between
groups. In this scenario, where imputation is done first
followed by normalization, the randomness introduced
by the imputation process covers up the true biological
trends as well as bias. Figure 4 shows that in raw data,
30% of the variation is attributable to the differences
between the groups (left panel). After imputation, the DE
trend (trend that looks like a step) is no longer detectable
(Figure 4, middle panel). This suggests that bias (second
trend in the raw data that explains 26% of variation) does
not allow us to perform imputation correctly. Normaliza-
tion performed after the imputation does not seem to be
able to remove bias well enough to discern the group dif-
ferences (Figure 4, right panel), suggesting that this
approach is not appropriate.
Normalization followed by imputation, on the other
hand, performs better (Figure 5). First, the DE trend
(trend that looks like a step) after normalization is more
apparent and explains a higher percentage of variation
(Figure 5, left panel). Second, the DE trend remains the
most significant trend after imputation (Figure 5, right
panel). It is sensible for the percent variation explained to
go down after imputation, as more data is available for
computing the trends. As we saw in Figure 4, imputed
values are still random draws from an appropriate distri-
bution, and they allow for more peptides and variation to
be added to the data. Eigentrends are computed only from
the peptides with no missing values, thus a smaller pull of
peptides is used in raw data and in data normalized before
imputation. We suggest that normalization be done first
followed by missing value imputations. Software tools
such as DanteR as well as stand-alone functions in R and
Matlab may be used to perform normalization, imputa-
tion, significance analysis and visualization.
Discussion
Quantitative proteomic data present complex challenges
to the data analyst. We have discussed two common
issues in the context of spectral peak intensity analysis,
involving biases due to systematic technical variation
and informative missingness patterns. Normalization is
the solution to biases, but the normalization techniques
employed must be simultaneously flexible enough to
capture arbitrary patterns and delicate enough to not
overfit the data. Importantly, some of the biases such as
sample/subject selection bias may not be corrected by a
normalization technique as in some cases subjects are
selected not entirely at random, such as subjects visiting
a doctor about a specific condition. Missing values,
meanwhile, greatly complicate the statistical analysis of
quantitative proteomic data, particularly as missingness
in this context is largely synonymous with censoring.
However, standard statistical techniques can be used to
facilitate valid statistical conclusions.
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